Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering

Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering

YORK, January 22, 2026 - Tharimmune, Inc. (NASDAQ: THAR), the first publicly traded company to leverage Canton Coin to support

the Canton Network's ability to digitize traditional financial markets, today announced the closing of its previously announced

underwritten registered direct offering which included the issuance of 1,800,000 shares of its common stock at a price of $2.92 per share

and pre-funded warrants to purchase up to 17,000,000 shares of common stock at a price of $2.9199 per pre-funded warrant.

gross proceeds to the Company from the offering are approximately $55 million, before deducting underwriting discounts and commissions

and other offering expenses payable by the Company. The offering will provide the Company with additional growth capital for the continued

expansion and development of its Canton-centric digital asset treasury strategy, as well as with working capital for general corporate

Inc. operates a differentiated digital asset treasury strategy by actively participating in the Canton Network - a privacy-enabled,

secure blockchain hosting trillions in assets on chain.

Street acted as sole bookrunning manager for the offering.

Hastings LLP served as counsel to Clear Street.

Smith served as counsel to Tharimmune.

securities described above were offered by the Company pursuant to a shelf registration statement that was filed with the Securities

and Exchange Commission (SEC) on January 9, 2026 and became effective on January 16, 2026 (File No. 333-292648). A prospectus supplement

and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on January 20, 2026 and may be

obtained by contacting Clear Street, Attn: Syndicate Department, 150 Greenwich Street, 45th floor, New York, NY 10007, by email at ecm@clearstreet.io;

or by accessing the SEC's website at https://www.sec.gov/.

press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale

of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification

under the securities laws of any such jurisdiction.

Inc. (NASDAQ: THAR) is the first publicly traded company to leverage Canton Coin and support the Canton Network to advance institutional

blockchain adoption and the digitization of financial markets. In addition to driving value through activities on the Canton Network,

Tharimmune also operates clinical-stage biotech research and development. For more information, visit www.tharimmune.com. References

to information included on, or accessible through, websites do not constitute incorporation by reference of the information contained

at or available through such websites, and you should not consider such information to be part of this press release.

statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions

of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company's strategy, plans,

objectives, initiatives and financial outlook. When used in this press release, the words "estimates," "projected,"

"expects," "anticipates," "forecasts," "plans," "intends," "believes,"

"seeks," "may," "will," "should," "future," "propose" and variations

of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking

statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of

known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company's control, that

could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers

are cautioned not to place undue reliance on any forward-looking statements.

should carefully consider the foregoing factors, and the other risks and uncertainties described in the "Risk Factors" sections

of the Company's filings with the SEC, including the registration statement and the other documents filed by the Company. These

filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially

from those contained in the forward-looking statements.